Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160302 · ClinicalTrials.gov registry record · Early Phase 1
Curcumin Biomarker Trial in Head and Neck Cancer
A Early Phase 1 study of Head and Neck Cancer, sponsored by Louisiana State University Health Sciences Center Shreveport.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01160302: Completed Early Phase 1 study of Head and Neck Cancer, sponsored by Louisiana State University Health Sciences Center Shreveport.
NCT01160302 is a Early Phase 1 study of Head and Neck Cancer that has completed, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 33 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01160302, a Early Phase 1 study of Head and Neck Cancer, has completed, sponsored by Louisiana State University Health Sciences Center Shreveport.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
There is considerable evidence that turmeric consumption may have a protective effect against cancer progression. The purpose of this study is to examine the short-term effects of supplementation with a turmeric extract, Curcumin C3 Complex®, on biomarkers of head and neck squamous cell carcinoma (HNSCC).
Primary Outcome
Change in tissue levels, between pre- and post-treatment biopsy
Conditions Studied
Interventions
- DRUG Microgranular Curcumin C3 Complex®
Study Locations (1)
Louisiana
- LSUHSC-Shreveport and Feist-Weiller Cancer Center - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-06 |
| Est. Completion | 2016-01 |
| Phase | Early Phase 1 |
What the finished NCT01160302 record still lists
NCT01160302 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Microgranular Curcumin C3 Complex® is the first listed.
NCT01160302 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT01160302 about?
NCT01160302 is a clinical study titled "Curcumin Biomarker Trial in Head and Neck Cancer". There is considerable evidence that turmeric consumption may have a protective effect against cancer progression. The purpose of this study is to examine the short-term effects of supplementation with a turmeric extract, Curcumin C3 Complex®, on biomarkers of head and neck squamous cell carcinoma (H...
What is the current status of trial NCT01160302?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 33 participants. The study started on 2010-06. Estimated completion is 2016-01.
What conditions does trial NCT01160302 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT01160302?
The interventions under investigation include: Microgranular Curcumin C3 Complex® (DRUG).
Who is sponsoring clinical trial NCT01160302?
This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01160302 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01160302's enrollment target sits among peer trials
33 169th of 250 higher than 79 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intraoral Hypothermia Device for Preserving Taste During Radiation
RECRUITING · Early Phase 1
-
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
RECRUITING · Early Phase 1
-
Smoking Cessation Treatment for Head & Neck Cancer Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
COMPLETED · Early Phase 1
-
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia